Home >
Medicine Info >
Mozasef 5 mg Rapitab
Loading interface...

Mozasef 5 mg Rapitab

Manufactured bySun Pharma Laboratories Ltd.
ContainsMosapride
Description
Mozasef 5 mg Rapitab is a Gastroprokinetic agent that increases the movement of food from the stomach to the intestine. It speeds up the process of gastric emptying and prevents reflux of food into the food pipe.
QUICK LINKS:
Side effectsConcernsUsageRelated products

Side effects

Major & minor side effects for Mozasef 5 mg Rapitab

  • Diarrhea
  • Abdominal pain and cramps
  • Dizziness
  • Headache
  • Nausea
  • Sleeplessness
  • Dry mouth
  • Loss of appetite
  • Unusual tiredness and weakness
  • Yellowing of skin and eyes
  • Irregular heartbeat
  • Skin rash, hives, or itching

Uses of Mozasef 5 mg Rapitab

What is it prescribed for?

  • Gastroesophageal Reflux Disease
  • Gastroparesis
  • Adjunct prior to barium enema x-ray examination
Read More
Concerns

Commonly asked questions

  • How long does it take for this medicine to take effect?
    The amount of time taken by this medicine to show its effect is not clinically established.
  • How long do the effects of this medicine last?
    The amount of time for which this medicine remains effective is not clinically established.
  • Is it safe to consume alcohol while taking this medicine?
    Consumption of alcohol is not recommended during treatment with this medicine due to the increased risk of severe adverse effects such as nausea, headache, liver dysfunction, jaundice, fatigue, etc.
  • Is this a habit forming medicine?
    No habit forming tendencies were reported.
  • Can this medicine be taken during pregnancy?
    This medicine is not recommended for use in pregnant women since the safety and efficacy of use are not clinically established.
  • Can this medicine be taken while breast-feeding?
    This medicine is not recommended for use in breastfeeding women since the safety and efficacy of use are not clinically established.

Allergy

This medicine is not recommended for use in patients with a known allergy to mosapride or any other inactive ingredients present along with it.

Gastrointestinal haemorrhage

This medicine is not recommended for use in patients having internal bleeding in the stomach or intestines due to the increased risk of worsening of the patient's condition.

Mechanical bowel obstruction

This medicine is not recommended for use in patients having a blockage or obstruction in the intestines due to the increased risk of worsening of the patient's condition.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women since the safety and efficacy of use are not clinically established.

Breast-feeding

This medicine is not recommended for use in breastfeeding women since the safety and efficacy of use are not clinically established.
General warnings

Use in elderly

This medicine should be used with extreme caution in the elderly patients since the risk of adverse effects is significantly high.

Bleeding of stomach or intestine

This medicine should not be used if gastrointestinal bleeding is evident or suspected since it may worsen the patient's condition. Symptoms of gastrointestinal bleeding may include bloody or coffee colored stools, vomiting blood, coughing up blood, etc.

Mechanical obstruction of intestine

This medicine should not be used in patients having an obstruction of the intestine since it may worsen the patient's condition. Symptoms of blockage may include severe bloating, nausea, vomiting, stomach pain and cramps, and constipation.

Other medicines

Mozasef 5 mg Rapitab may interact with many other medicines and may cause undesirable side effects. Hence, it is advised that you report the use of all your current medicines including supplements and herbs to the doctor before beginning treatment with this medicine.

Cardiovascular effects

This medicine is reported to have caused severe side effects on the heart and blood vessels. Extreme caution is advised while using this medicine since some of these side effects may be fatal. This risk is especially higher in patients with a history of heart diseases. Close monitoring of heart function may be necessary based on the clinical condition. Replacement with a suitable alternative may be required in some cases.

Liver disease

This medicine should be used with extreme caution in patients having an impairment of the normal liver function since it may worsen the patient's condition.

Kidney disease

This medicine should be used with extreme caution in patients having an impairment of the normal kidney function since it may worsen the patient's condition.

Missed Dose

Take the missed dose as soon as you remember. If it is almost time for the next scheduled dose, then it is advisable to skip the missed dose. Do not use extra medicine to make up for the missed dose.

Overdose

Contact your doctor immediately if an overdose with this medicine is suspected. You may require emergency medical intervention if the symptoms are severe. Symptoms may include nausea, vomiting, nervousness, headache, borborygmi, etc.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Use of alcohol while taking this medicine increases the risk of adverse effects significantly.

Instructions

Consumption of alcohol is not recommended during treatment with this medicine due to the increased risk of severe adverse effects such as nausea, headache, liver dysfunction, jaundice, fatigue, etc.
Interaction with Medicine

Erythromycin

Haloperidol

Ketoconazole

Quinine

Amiodarone

Anticholinergic drugs

Terfenadine

Sotalol

Disease interactions

Impaired liver function

This medicine should be administered with extreme caution in patients having an impairment of normal liver function due to the increased risk of worsening of the patient's condition. Use is not recommended if the impairment is severe.

Respiratory Disorders

This medicine is not recommended for use in patients with respiratory disorders (both hypoxemia and hypercapnia). Appropriate tests should be performed to rule out respiratory failure syndrome before treatment with this medicine is initiated.

Impaired kidney function

This medicine should be administered with extreme caution in patients having an impairment of normal kidney function due to the increased risk of worsening of the patient's condition. Use is not recommended if the impairment is severe.
Food interactions
Consumption of grapefruit or grapefruit juice is not recommended during treatment with this medicine due to the increased risk of severe adverse effects such as an irregular heart rhythm, restlessness, fatigue, headache, nausea, etc.
Lab interactions
Information not available.
This is not an exhaustive list of possible drug interactions. You should consult your doctor about all the possible interactions of the drugs you’re taking.
Take Mozasef 5 mg Rapitab exactly as prescribed by the doctor. Do not take in larger or smaller quantities than recommended. Contact your doctor if the symptoms do not improve after 2 weeks of administration. Report any unusual symptoms to the doctor immediately.
Miscelleneous

Can be taken with or without food, as advised by your doctor

To be taken as instructed by doctor

Does not cause sleepiness

How it works
This medicine acts by increasing the concentration of a certain natural chemical which increases stomach muscle movement and improves gastric emptying. This helps in the faster movement of food from the stomach to the intestine.
Legal Status

Approved

Unknown

Unknown

Approved

Classification

Category

Gastrointestinal agents

Schedule

Schedule H

Tack J, Camilleri M, Chang L, Chey W, Galligan J, Lacy B et al. Systematic review: cardiovascular safety profile of 5-HT4 agonists developed for gastrointestinal disorders. Alimentary Pharmacology & Therapeutics [Internet]. 2012 [cited 4 August 2017];35(7):745-767. Available from:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491670/

YOSHIDA N, ITO T. Mosapride citrate (AS-4370), a new gastroproltinetic agent, is a partial 5-HT4 receptor agonist in the gut. Neurogastroenterology & Motility [Internet]. 2008 [cited 4 August 2017];6(3):197-204. Available from:

https://www.ncbi.nlm.nih.gov/pubmed/16898619

Mosapride - DrugBank [Internet]. Drugbank.ca. 2017 [cited 11 September 2017]. Available from:

https://www.drugbank.ca/drugs/DB11675

Compound Report Card [Internet]. Ebi.ac.uk. 2017 [cited 11 September 2017]. Available from:

https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL60889

Mosapride [Internet]. Pubchem.ncbi.nlm.nih.gov. 2017 [cited 11 September 2017]. Available from:

https://pubchem.ncbi.nlm.nih.gov/compound/119584#section=Top

[Internet]. 2017 [cited 13 September 2017]. Available from:

http://www.fouda.com/sites/default/files/11245.pdf

[Internet]. 2017 [cited 13 September 2017]. Available from:

http://www.ds-pharma.com/ir/news/pdf/ene20090422.pdf
Loading related questions...
Something doesn’t feel right?
Report an error

Information on this page was last updated on 16 Feb 2022

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.